'Today's EC approval for the use of Cabometyx in combination with Opdivo provides an important new first-line treatment option for patients living with advanced renal cell carcinoma,' said
(C) 2021 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
114.5 EUR | -0.52% | +1.33% | +6.12% |
02/05 | Ipsen Announces Executive Changes | CI |
02/05 | Ipsen: new President for North America | CF |
'Today's EC approval for the use of Cabometyx in combination with Opdivo provides an important new first-line treatment option for patients living with advanced renal cell carcinoma,' said
(C) 2021 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
+6.12% | 10.19B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |